AP NEWS

Angiotensin Receptor Agonist - Pipeline Insight, 2019 - ResearchAndMarkets.com

February 8, 2019

DUBLIN--(BUSINESS WIRE)--Feb 8, 2019--The “Angiotensin Receptor Agonist - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Angiotensin Receptor Agonist - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Angiotensin Receptor Agonist development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Clinical Non-clinical Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the Report

Provides a snapshot of the therapeutics pipeline activity for Angiotensin Receptor Agonist Features the Angiotensin Receptor Agonist pipeline across the complete product development cycle including all clinical and non-clinical stages Offers detailed therapeutic product profiles of Angiotensin Receptor Agonist with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration Coverage of dormant and discontinued pipeline projects across Angiotensin Receptor Agonist

Reasons to Buy

Establish a comprehensive understanding of the current pipeline scenario across Angiotensin Receptor Agonist to formulate effective R&D strategies Assess challenges and opportunities that influence Angiotensin Receptor Agonist research & development (R&D) Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage Identify and understand the sought after therapy areas and indications for Angiotensin Receptor Agonist Identify the product attributes and use it for target finding, drug repurposing, and precision medicine Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Angiotensin Receptor Agonist to enhance and expand business potential and scope Plan prospective mergers and acquisitions effectively by identifying key players in this area and their most promising pipeline therapeutics and developmental progress

Topics Covered

1. Report Introduction

2. Angiotensin Receptor Agonist - Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Angiotensin Receptor Agonist

4. Comparative Analysis

5. Angiotensin Receptor Agonist Pipeline Products in Clinical Stages

Product Description Research and Development Product Development Activities

6. Angiotensin Receptor Agonist Pipeline Products in Non-clinical Stages

Product Description Research and Development Product Development Activities

7. Therapeutic Assessment: Active Products

Pipeline Assessment by Route of Administration Pipeline Assessment by Stage and Route of Administration Pipeline Assessment by Molecule Type Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

Product Description Research and Development Product Development Activities Reason for dormancy/discontinuation

Companies Mentioned

Mitsubishi Tanabe Pharma Corporation La Jolla Pharmaceutical Company Sanofi-aventis

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/mbpd8r/angiotensin?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190208005309/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/08/2019 10:26 AM/DISC: 02/08/2019 10:26 AM

http://www.businesswire.com/news/home/20190208005309/en

AP RADIO
Update hourly